Updated plans for East West Rail have been revealed as a fresh consultation gets under way - and they include two tunnels to ...
AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Senior Independent Non-Executive Director, Philip Broadley, has made a notable ...
Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...
Shares of AstraZeneca PLC AZN rallied 1.54% to £101.44 Wednesday, on what proved to be an all-around favorable trading ...
The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...
AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...
In the US, AstraZeneca has approximately 17,800 employees working across 17 R&D, manufacturing and commercial sites spanning ...
GlobalData on MSN23h
MSD and AstraZeneca report positive topline data from Koselugo trial for NF1Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET trial, assessing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback